3.29
0.23 (7.52%)
Penutupan Terdahulu | 3.06 |
Buka | 3.10 |
Jumlah Dagangan | 1,137,936 |
Purata Dagangan (3B) | 596,505 |
Modal Pasaran | 348,832,128 |
Harga / Jualan (P/S) | 6.21 |
Harga / Buku (P/B) | 1.18 |
Julat 52 Minggu | |
Tarikh Pendapatan | 13 Jan 2025 |
Margin Keuntungan | -110.92% |
Margin Operasi (TTM) | -118.33% |
EPS Cair (TTM) | -0.400 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -8.40% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 9.44% |
Nisbah Semasa (MRQ) | 12.23 |
Aliran Tunai Operasi (OCF TTM) | -31.46 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.08 M |
Pulangan Atas Aset (ROA TTM) | -13.12% |
Pulangan Atas Ekuiti (ROE TTM) | -19.63% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Menurun | Menurun |
Medical Devices (Global) | Menurun | Menurun | |
Stok | MaxCyte, Inc. | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -0.5 |
Purata | -0.50 |
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 1.45% |
% Dimiliki oleh Institusi | 75.79% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
River Global Investors Llp | 31 Dec 2024 | 3,253,192 |
Mudita Advisors Llp | 31 Dec 2024 | 3,223,407 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
09 Jul 2025 | Pengumuman | MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 |
11 Jun 2025 | Pengumuman | MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies |
07 May 2025 | Pengumuman | MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance |
07 May 2025 | Pengumuman | MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |